Literature DB >> 2444839

Inhibition of theophylline metabolism by interferon.

S J Williams1, J A Baird-Lambert, G C Farrell.   

Abstract

1 day after a single intramuscular injection of recombinant human interferon alpha A in 5 patients with stable chronic active hepatitis B and 4 healthy controls theophylline clearance was significantly reduced and theophylline elimination half-life was significantly increased. There was a clear relation between pre-treatment and post-treatment theophylline clearance rates, indicating that the greatest effect of interferon was in subjects who were fast metabolisers of theophylline. These observations support the contention that the actions of endogenous interferon may account for the effects of immunisations and viral infections on hepatic drug metabolism. Moreover, treatment with interferon may cause clinically important drug interactions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444839     DOI: 10.1016/s0140-6736(87)91422-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  27 in total

Review 1.  Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.

Authors:  J F Westphal
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

Review 2.  The role of pharmacokinetics in the development of biotechnologically derived agents.

Authors:  R J Wills; B L Ferraiolo
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 3.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of interferons.

Authors:  R J Wills
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

5.  Depression of drug metabolizing activity in the human liver by interferon-alpha.

Authors:  H Okuno; Y Kitao; M Takasu; H Kano; K Kunieda; T Seki; Y Shiozaki; Y Sameshima
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  Potentiation of warfarin by interferon.

Authors:  Y Adachi; Y Yokoyama; T Nanno; T Yamamoto
Journal:  BMJ       Date:  1995-07-29

Review 7.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 8.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 9.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

10.  Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity.

Authors:  Karin Hellman; Ewa Roos; Anna Osterlund; Anneli Wahlberg; Lars L Gustafsson; Leif Bertilsson; Sten Fredrikson
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.